Form 8-K - Current report:
SEC Accession No. 0000950170-25-046176
Filing Date
2025-03-27
Accepted
2025-03-27 16:58:56
Documents
11
Period of Report
2025-03-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kytx-20250327.htm   iXBRL 8-K 47786
  Complete submission text file 0000950170-25-046176.txt   162153

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT kytx-20250327.xsd EX-101.SCH 24834
13 EXTRACTED XBRL INSTANCE DOCUMENT kytx-20250327_htm.xml XML 4715
Mailing Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608
Business Address 5980 HORTON STREET SUITE 550 EMERYVILLE CA 94608 5106268331
Kyverna Therapeutics, Inc. (Filer) CIK: 0001994702 (see all company filings)

EIN.: 831365441 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41947 | Film No.: 25780253
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)